Palvella Therapeutics, Inc.

PVLA

US6979471090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
134.39 ^USD	-0.41%		-0.47%	+28.39%

Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing	MT
Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $500,000, According to a Recent SEC Filing	MT

Mizuho Initiates Palvella Therapeutics at Outperform, Price Target is $205

Published on 01/07/2026 at 08:29 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Palvella Therapeutics, Inc.

Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing	MT
Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $500,000, According to a Recent SEC Filing	MT
Feb. 26	Top Midday Gainers	MT
Feb. 26	Palvella Therapeutics announces pricing of upsized public offering	RE
Feb. 25	Chardan Raises Price Target on Palvella Therapeutics to $210 From $174, Keeps Buy Rating	MT
Feb. 24	Palvella Therapeutics announces proposed public offering	RE
Feb. 24	Palvella Therapeutics Launches $150 Million Public Offering	MT
Feb. 24	Mizuho Adjusts Price Target on Palvella Therapeutics to $250 From $205, Maintains Outperform Rating	MT
Feb. 24	Palvella Therapeutics Says Qtorin Meets Primary Endpoint in Phase 3 Study on Microcystic Lymphatic Malformations	MT
Feb. 24	Palvella Therapeutics, Inc. Announces Positive Topline Results from Phase 3 SELVA study of QTORIN 3.9% Rapamycin Anhydrous Gel	CI
Feb. 24	Palvella Therapeutics announces positive topline results from phase 3 Selva clinical study of Qtorin(TM)	RE
Feb. 02	Palvella Therapeutics, Inc. Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis	CI
Jan. 09	Palvella Expects Phase 3 Results From Microcystic LMs Treatment Gel in March, NDA Submission in H2	MT
Jan. 09	Palvella Therapeutics provides corporate update and 2026 outlook	RE
Jan. 07	Mizuho Initiates Palvella Therapeutics at Outperform, Price Target is $205	MT

Chart Palvella Therapeutics, Inc.

Duration

Period

PVLA: Dynamic Chart

Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

Employees

Sector

Biotechnology & Medical Research

More about the company